Wanbury Ltd
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]
- Market Cap ₹ 958 Cr.
- Current Price ₹ 292
- High / Low ₹ 330 / 131
- Stock P/E 31.4
- Book Value ₹ 18.1
- Dividend Yield 0.00 %
- ROCE 34.9 %
- ROE 70.0 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 29.9% CAGR over last 5 years
Cons
- Stock is trading at 16.0 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.3% over past five years.
- Tax rate seems low
- Promoters have pledged 76.7% of their holding.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Sep 2014 18m | Mar 2015 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
661 | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 485 | 557 | 600 | |
637 | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 459 | 484 | 523 | |
Operating Profit | 25 | 21 | 33 | 19 | -68 | 16 | 23 | 18 | 36 | 26 | 73 | 76 |
OPM % | 4% | 9% | 8% | 4% | -18% | 4% | 6% | 5% | 7% | 5% | 13% | 13% |
-78 | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | -3 | 26 | 3 | |
Interest | 48 | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 |
Depreciation | 23 | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 |
Profit before tax | -125 | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 56 | 30 |
Tax % | 2% | 28% | 0% | 1% | -1% | -1% | 0% | 2% | -0% | 1% | 1% | -3% |
-128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 56 | 31 | |
EPS in Rs | -63.95 | 1.60 | -3.58 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 17.09 | 9.32 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | 5% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 25% |
5 Years: | 30% |
3 Years: | 75% |
TTM: | -8% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 74% |
3 Years: | 65% |
1 Year: | 85% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 70% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 20 | 20 | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 | 33 |
Reserves | -212 | -214 | -209 | -176 | -208 | -233 | -168 | -181 | -56 | -66 | -5 | 26 |
389 | 381 | 362 | 300 | 250 | 260 | 190 | 192 | 100 | 95 | 116 | 177 | |
209 | 209 | 215 | 265 | 207 | 236 | 232 | 253 | 276 | 241 | 199 | 178 | |
Total Liabilities | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 |
174 | 164 | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | 201 | |
CWIP | 13 | 19 | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 | 5 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
219 | 213 | 193 | 216 | 84 | 105 | 101 | 111 | 183 | 135 | 174 | 208 | |
Total Assets | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
68 | 40 | 43 | 43 | 32 | 30 | 44 | 17 | 41 | 20 | 4 | 26 | |
-6 | -5 | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | -17 | -51 | |
-71 | -30 | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | 15 | 26 | |
Net Cash Flow | -9 | 5 | -5 | 3 | -2 | -0 | -0 | 7 | 13 | -21 | 2 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 57 | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 52 | 59 | 70 |
Inventory Days | 42 | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 | 47 |
Days Payable | 113 | 301 | 172 | 260 | 174 | 209 | 253 | 221 | 218 | 179 | 196 | 172 |
Cash Conversion Cycle | -14 | -55 | -38 | -125 | -118 | -131 | -177 | -148 | -113 | -101 | -94 | -55 |
Working Capital Days | -3 | -26 | -45 | -132 | -195 | -175 | -212 | -168 | -103 | -102 | -20 | 13 |
ROCE % | 4% | 12% | 57% | -1% | 26% | 31% | 27% | 46% | 21% | 61% | 35% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
24h - Wanbury's Patalganga site granted ANVISA GMP certificate valid till May 2027.
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 16 May
-
Integrated Filing (Financial)
15 May - Wanbury's audited FY25 results approved; revenue Rs 599.5 Cr, profit Rs 30.5 Cr; USFDA, ANVISA inspections cleared; Rs 175 Cr NCDs issued.
-
Announcement under Regulation 30 (LODR)-Change in Management
15 May - Re-appointment of Secretarial, Internal, Cost, and Tax auditors for FY 2025-26 and beyond.
-
Board Meeting Outcome for Outcome Of Board Meeting 15 May 2025
15 May - Wanbury Limited approved audited FY25 financials; stable profits; raised Rs.175 Cr NCDs; cleared USFDA, ANVISA inspections.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Business Overview:[1]
WL is a pharmaceutical company with a presence in the API global market and domestic branded Formulation. It’s majorly into Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India
Formulation presence